# A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

> **NCT04236141** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 42 (actual)

## Conditions studied

- Diffuse, Large B-Cell, Lymphoma

## Interventions

- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04236141
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-10
- **Primary completion:** 2021-07-12
- **Final completion:** 2022-02-07
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Sponsor's decision, no safety concerns
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236141, "A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04236141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*